The Joint Corp. | NASDAQ: JYNT | thejoint.com

Q3 2023 Investor Presentation

As of September 30, 2023 | Reported on November 9, 2023





Safe Harbor Statements

Certain statements contained in this presentation are "forward-looking statements" about future events and expectations. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. . Specific forward looking statements made in this press release include, among others, our belief that the strength of our franchise concept to revolutionize access to chiropractic care remains strong; our strategic plan to leverage our biggest strength – our profound understanding of franchising – to drive long-term growth for both our franchisees and The Joint as a public company; our plan to refranchise or sell the majority of our company-owned or managed clinics and to retain a portion of the high-performing corporate clinics; our belief that with a focus on profitability, we are taking clear action to strengthen the health of our network, improve the performance of our public company, and increase our ability to reinvest in the business and create value for our stockholders; and our guidance for fiscal 2023 for revenue, adjusted EBITDA, franchised clinic openings, and company-owned or managed greenfield clinic openings. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage and an increase in operating expenses due to measures we may need to take to address such shortage; inflation, exacerbated by COVID-19 and the current war in Ukraine, which has increased our costs and which could otherwise negatively impact our business; the potential for further disruption to our operations and the unpredictable impact on our business of the COVID-19 outbreak and outbreaks of other contagious diseases; our failure to profitably operate company-owned or managed clinics; short-selling strategies and negative opinions posted on the internet, which could drive down the market price of our common stock and result in class action lawsuits; our failure to remediate future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence; and other factors described in our filings with the SEC, including in the section entitled "Risk Factors" in our Annual Report on Form 10-K/A for the year ended December 31, 2022 filed with the SEC on September 26, 2023 and subsequently-filed current and quarterly reports. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

Business Structure


The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming. The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.







Quality, convenient, affordable chiropractic care in a retail setting





Serving patients seeking pain relief and ongoing health and wellness





A proven membership-based, walk-in, no-insurance model in an open bay setting


Strong Operational KPIs

1.6M 845K 12.2M 35% 84% unique patients new patients of new patients system-wide gross sales adjustments treated in 2022 in 2022 were new to chiropractic¹ from monthly in 2022 memberships in 2022 Up from 10.9M in 2021 Up from 1.4M in 2021 Compared to 807K in 2021 ~296K patients in 2022 Compared to 85% in 2021 had never been to a chiropractor before



Upside for Future Growth

\$19.5B growing chiropractic market¹



50%

of Americans don't know what the word "chiropractic" means

> Gallup-Palmer College of Chiropractic Report 2017

30%

understand chiropractic
but are scared

16%


saw a chiropractor in the last 12 months

Chiropractic Report 201



Substantial Opportunity for Market Share Growth

- \$134B annual spending on back pain ¹
- \$19.5B annual spending on chiropractic care²
- ~4% of chiropractic offered at chains³ vs.
 ~12% for dentistry chains (DSOs)⁴
- 80% of Americans experience back pain at least once in their lifetime⁵





¹JAMA US Healthcare spending by Payer and Health Condition, 1996-2016, March 2020

² IBIS US Industry Report, Chiropractors in the US, March 2022


³ Internal Chiropractic Competitive Analysis, August 2019

⁴ Apex Reimbursement Specialists, Inc., 2018 | ⁵ American Chiropractic Association

Only 4.9% of Franchise Concepts Have 500+ Units

Percentage of Franchise Brands by # of Units

Only 94 brands have over 1000 units.






JYNT Sales ~2.3x Independent Collections per Clinic







Collections





Top Franchise Recognition... Again














Growing Market Opportunity



Mid-term Market ~1950 Potential Clinics

The Joint Patient Base

With usable addresses

- All 50 States, DC and Puerto Rico
- All Canadian Provinces and Territories
- 66 Countries on 6 Continents

Similar Points of Distribution

- Analyze demographics and psychographics
- Model attributes
- Roll across country


The Joint: First Mover Advantage

Companies	Clinics at 9/30/23	Clinics at 12/31/17	Change in Clinics	States	Franchise	Owned/ Managed	Insurance	Private Pay
The Joint Corp.	914	399	515	40	✓	✓		✓
Airrosti	152	177	(25)	4		✓	✓	✓
HealthSource Chiropractic	135	295	(160)	32	✓		✓	
100% Chiropractic	114	*	0	22	✓		✓	✓
ChiroOne	99	41	58	7		✓	✓	
AlignLife Chiropractic	36	23	13	13	✓	✓	✓	✓
Chiropractic Company	21	*	0	1		✓	✓	✓
Aligned Modern Health	18	*	0	1		✓	✓	✓
NuSpine	33	3	30	10	✓			✓
Chiropractic Partners	12	*	0	1		✓	✓	✓
20 Dollar Chiropractic	10	*	0	1	✓			✓
Curis Functional Health (Formerly The BackSpace)	53	*	0	11		✓	✓	✓
Chiro Now!	9	*	0	1	✓	✓		✓
ChiroWay	11	8	3	3	✓			✓
Express Chiropractic	6	0	6	1	✓			✓
SnapCrack Chiropractic	8	*	0	1	✓			✓
Independent Offices	39,458	38,801	657	50				

	Q3 2023	Q3 2022
Franchise Licenses Sold	12	12
Total New Franchised Clinics Opened	24	33
Greenfield Clinics Opened	2	5
Franchised Clinics Acquired	0	3
Clinics in Development	202	252
THEJOINT.		

chiropractic

26 New Clinics in Q3 2023



¹ In Q3 2023 and Q3 2022, The Joint closed two franchised clinics for both periods. The closure rate remains one of the lowest in the franchise community at less than 1 percent.

914

Locations

778

Franchised Clinics


136

Corporate Clinics

As of 9/30/2023




Growing National Footprint




Pipeline for Growth


Franchise Licenses Sold Annually



Clinics in Active Development¹



Gross Cumulative Franchise Licenses Sold¹



52% sold by Regional Developers in YTD 2023

68% of clinics supported by 17 RDs as of Sept. 30, 2023

RD territories cover 55% of Metropolitan Statistical Areas (MSAs) as of Sept. 30, 2023



~\$250k - \$275k initial build-out

Chart includes:

- 2% of gross sales for the National Marketing Fund
- Local marketing expenses, wages, rent and G&A expenses


Chart excludes:

- \$599 per month tech fee
- 7% royalty on gross sales
- \$39.9K per license, prior to year 1 sales
- Assumes breakeven monthly gross sales¹ of \$30k - \$38k



Strong Clinic Economics

System-wide Sales & Potential Company-owned/Managed Contribution¹ (5 yr. avg., \$ in 000s)



¹ Breakeven varies on a clinic-by-clinic basis based on actual gross sales and operating expenses. This represents operating income excluding income taxes and depreciation..

Building upon Foundation for Growth

8%

Increase in system-wide sales¹ Q3 2023 over Q3 2022 0%

Increase in system-wide comp sales² for all clinics >13 months in operation Q3 2023 over Q3 2022 (5)%

Decrease in system–wide comp sales² for all clinics >48 months in operation Q3 2023 over Q3 2022





¹System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. | ² Comparable sales include only the sales from clinics that have been open at least 13 or 48 full months and exclude any clinics that have permanently closed.

Reiterating 2023 Financial Guidance

\$ in M	2022 Actual	2023 Low Guidance	2023 High Guidance
Revenues	\$101.9	\$115.0	\$118.0
Adjusted EBITDA	\$11.5	\$11.0	\$12.5
New Franchised Clinic Openings	121	100	120
New Greenfield Clinic ¹	16	8	12



¹Historically, company-owned or managed clinic openings included a combination of both greenfields and acquisitions. The company will continue to acquire previously franchised clinics. However, as these transactions are opportunistic, management will no longer include the acquired clinic estimate in guidance. To provide greater clarity, the 2023 company-owned or managed guidance includes greenfield clinic openings only.

People will continue to seek more noninvasive, holistic ways to manage their pain.

We'll be there to treat them.


THE JOITT chiropractic

Leading Market Growth

The Joint Corp. 12-yr. CAGR 62% vs. Industry 5-yr. CAGR 5.1%

System-wide Sales

(\$ in M)



¹ For the period ended Dec. 31, 2022

² March 2023 Kentley Insights Chiropractic Care Market Research Report

Driving Long-term Shareholder Value

The most powerful brand-building tool is **our storefronts**.





Appendix



Q3 2023 Financial Results as of Sept. 30, 2023

\$ in M ¹	Q3 2023	Q3 2022	Differe	nces
Revenue • Corporate clinics • Franchise fees	\$29.5 17.9 11.6	\$26.5 15.8 10.6	\$3.0 2.0 1.0	11% 13% 9%
Cost of revenue	2.6	2.3	0.3	11%
Sales and marketing	4.1	3.3	0.9	27%
Depreciation and amortization	2.3	1.8	0.6	32%
G&A	20.2	17.8	2.4	13%0
Loss on disposition or impairment ²	0.9	0.3	0.6	NA
Operating (Loss)/Inc.	(O.9)	0.7	(1.6)	NA
Tax benefit	(O.2)	0.0	(0.2)	NA
Net (Loss)/Income	(O.7)	0.7	(1.4)	NA
Adj. EBITDA ³	2.9	3.1	(0.2)	(7)%



¹ Due to rounding, numbers may not add up precisely to the totals.

² Loss on disposition or impairment, including those corporate clinics that were announced to be held for sale in September 2023.

³ Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

YTD 2023 Financial Results as of Sept. 30, 2023

\$ in M¹	YTD 2023	YTD 2022	Differe	nces
Revenue • Corporate clinics • Franchise fees	\$87.1 52.8 34.3	\$73.6 42.9 30.6	\$13.5 9.9 3.6	18% 23% 12%
Cost of revenue	7.7	6.7	1.0	14%
Sales and marketing	13.2	10.7	2.5	23%
Depreciation and amortization	6.9	4.6	2.3	51%
G&A	60.2	51.9	8.3	16%
Loss on disposition or impairment ²	1.1	0.4	(0.8)	NA
Operating (Loss)/Inc.	(1.9)	(0.7)	(1.2)	NA
Tax expense (benefit)	0.5	(0.6)	(1.1)	NA
Net Income/(Loss)	1.3	(O.1)	1.4	NA
Adj. EBITDA ²	8.2	7.5	0.6	8%



¹ Due to rounding, numbers may not add up precisely to the totals.

² Loss on disposition or impairment, including those corporate clinics that were announced to be held for sale in September 2023.

³ Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

Executive Team

















Peter D. Holt	Jake Singleton	Lori Abou Habib	Krischelle Tennessen	Charles Nelles	Jorge Armenteros	Eric Simon	Dr. Steve Knauf
President & CEO Tasti D-Lite Planet Smoothie Mail Boxes Etc. The UPS Store I Can't Believe It's Yogurt	CFO • EY • American Institute of CPAs	CMO SONIC® Americ a's Drive-In®, part of the Inspire Brands CKE Restaurants, Inc. Eateries, Inc.	CHRO Five Below Marvin Windows & Doors Kum & Go Walmart Target	CTO • American Express Global Business Travel • Western Union • The Children's Hospital of Denver • PacifiCare Health Systems	SVP, Operations Togo's Dunkin' Donuts Baskin Robbins Pollo Campero	VP, Franchise Sales Aamco Mail Boxes Etc. UPS Store Extreme Pita	VP of Chiropractic & Compliance • Arizona Board of Chiropractic Examiners • Northwestern Health Sciences University • International Chiropractors Assn. • American Chiropractic Assn. • Health Care Compliance Assn.
MA, Univ. of London BA, Univ. of Washington	MA, Univ. of Arizona BS, Univ. of Arizona	MBA, Webster International Univ. BA, Univ. of Central Oklahoma	MAOM, Univ. of Phoenix BA, Univ. of Minnesota - Winona	BA, Univ. of Phoenix, Certified PMP		BA, Univ. of Rhode Island	DC, Northwestern Health Sciences Univ. BS, Northwestern Health Sciences Univ.



© 2023 The Joint Corp. All Rights Reserved.

Board of Directors













Matthew E. Rubel	Ronald V. DaVella, CPA	Suzanne M. Decker	Peter D. Holt	Abe Hong	Glenn J. Krevlin
Lead Director, 2017	Director, 2014	Director, 2017	Director, 2016	Director, 2018	Director, 2019
 Executive Chair KidKraft, Inc. Chair, Holley Inc. & Mid Ocean Ptrs. PE Consumer Group Former Dir. Hudson's Bay Co., HSNi & Treehouse Foods Former: Roark Capital, TPG Capital, TPG Growth, Varsity Brands, Collective Brands, Cole Haan, J Crew, Popular Club Plan and more Pres. Appointee, House Advisory Council on Trade Policy Negotiation 	 Financial Advisor: Manufacturing Succession Holding, and Universal Health Vice Chair of the Strategic Advisory Board of Aura Ventures Dir. Alkaline Water Co., Universal Health Group, Delta Dental of Arizona, and NorthStar Security Former: Deloitte & Touche Mobile Home Parks NanoFlex Power Corp. and Amazing Lash Studio CFO & franchisee 	 Former Exe. Project Sponsor and Chief HR Officer, Aspen Dental Mgmt HR & Talent Acquisition Advisor, Bond Veterinary Former Dir. Refresh Mental Health Davis Vision Companies 	 Pres. & CEO, The Joint Corp. Former Mgmt.: Tasti D-Lite Great Hills Partners Mail Boxes, Etc. (now The UPS Store) Director Intl.I Franchise Assn. (IFA) Chair, International Affairs Network (IAN) 	 EVP & CTO, Learning Care Group Former Mgmt.: Discount Tire Company Red Rock Resorts Starbucks Corp. Technologent 	 Founder, Managing Partner, & PM Glenhill Capital Advisors Dir. Ember Technologies Former Mgmt. or Dir. Centric Brands Design within Reach Restoration Hardware Cumberland Associates The Goldman Sachs Group

BS, Ohio University
MBA, University of Miam

BS, Queens College MBA, Pace University

BS, Russell Sage College

BA, Univ. of Washington MA, University of London

ngton BE, U.S. Military Academy at West pondon Point

at West BA, Wesleyan University MBA, New York University

Revolutionizing Access to Chiropractic Care

Features	Industry Problems	The Joint's Solutions
Affordability (per appointment)	\$64 Average ¹	\$36 Average
Convenient Locations	Medical Centers / Offices	Retail Locations
Multiple Locations	Limited Locations	914 Clinics
Walk-in / No Appointment	Appointments Required	No Appointments
Insurance / Caps / Co-pays	Yes	Private Pay
Inviting, Consumer-centric Design	Clinical	Approachable, Consumer Friendly
Service Hours	Limited / Inconsistent	Open 6-7 Days + Nights & Weekends ²
Average Patient Visits per Clinic	115 per week ¹	321 per week ³



Patient Demographics

	The Joint
Median Age	37.6 Years
Generation Mix	
Gen Z	19%
Millennial	45%
Gen X	25%
Baby Boomer	11%
Gender	
Female	49%





Transformative Opportunity for Chiropractors

	Industry	The Joint	
Annual Salary	Median \$81,240 ¹	Starting \$85,000 ²	Our r through routing quality iropractic C
Accessibility	Appointments requiredMedical centers & officesTraditional office hours	 No appointments Clustered, high-visibility retail locations Open evenings + weekends³ 	quality iropractic C
Practice & Insurance	 Challenges of managing a business without support Difficulty attracting new patients Insurance hassles Slow payment cycle 	 Proprietary CRM and POS software Ongoing training and coaching Ability to perfect technique Less administration Higher patient focus Better cash flow 	Tit jo chiropra



¹Bureau of Labor Statistics, U.S. Department of Labor, 2021

² Based on Joint Corp. company-owned or managed actual salaries | ³ Hours vary by clinic

Performance Metrics and Non-GAAP Measures

This presentation includes commonly discussed performance metrics. System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

This presentation includes non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company's underlying operating performance and operating trends than GAAP measures alone. Reconciliations of net loss to EBITDA and Adjusted EBITDA are presented where applicable. The Company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase net gain, gain/(loss) on disposition or impairment, stock-based compensation expenses and employee retention credits.


EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are frequently used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company's financial statements filed with the SEC.

Information reconciling forward-looking Adjusted EBITDA to net income/(loss) is unavailable to the company without unreasonable effort. The company is not able to provide a quantitative reconciliation of adjusted EBITDA to net income/(loss) because certain items required for such reconciliation are uncertain, outside of the company's control, and/or cannot be reasonably predicted, including but not limited to [the provision for (benefit from) income taxes. Preparation of such reconciliation would require a forward-looking statement of income and statement of cash flows prepared in accordance with GAAP, and such forward-looking financial statements are unavailable to the company without unreasonable effort.



Q3 2023 Segment Results as of Sept. 30, 2023

\$ in 000s




Total Revenues Total Operating Costs Operating Income (Loss) Other Income Expense, net Income (Loss) Before Income Tax Expense **Total Income Taxes** Net Income (Loss) **Net Interest Expense** Income Taxes **Total Depreciation and Amortization Expense EBITDA** Stock Based Compensation Exp Loss on Disposition/Impairment **Acquisition Expenses** Other Expense, net Adjusted EBITDA

Corporate Clinics	Franchise Operations	Unallocated Corporate	c	The Joint Consolidated
\$ 17,882	\$ 11,592	\$ -	\$	29,474
(18,814)	(6,453)	(5,106)		(30,372)
(931)	5,139	(5,106)		(898)
-	-	(6)		(6)
(931)	5,139	(5,112)		(904)
-	-	(188)		(188)
(931)	5,139	(4,924)		(716)
-	-	6		6
-	-	(188)		(188)
2,068	191	91		2,349
1,136	5,330	(5,015)		1,451
-	-	526		526
905	-	-		905
2	13	-		15
-	-	-		-
\$ 2,044	\$ 5,342.8	\$ (4,489)	\$	2,897



YTD Segment Results through Sept. 30, 2023

\$ in 000s



Total Revenues Total Operating Costs Operating Income (Loss) Other Income Expense, net Income (Loss) Before Income Tax Expense **Total Income Taxes** Net Income (Loss) Net Interest Expense **Income Taxes Total Depreciation and Amortization Expense EBITDA** Stock Based Compensation Exp Loss on Disposition/Impairment Acquisition Expenses Other Expense, net Adjusted EBITDA

Corporate Clinics	Franchise Operations	Unallocated Corporate	The Joint Consolidated		
\$ 52,813	\$ 34,269	\$ -	\$ 87,082		
(54,145)	(20,356)	(14,507)	(89,008)		
(1,332)	13,913	(14,507)	(1,926)		
-	-	3,708	3,708		
(1,332)	13,913	(10,799)	1,783		
-	-	493	493		
(1,332)	13,913	(11,292)	1,289		
-	-	71	71		
-	-	493	493		
6,028	598	268	6,894		
4,696	14,511	(10,460)	8,747		
-	-	1,209	1,209		
1,115	-	-	1,115		
6	867	-	873		
-		(3,779)	(3,779)		
\$ 5,817	\$ 15,378	\$ (13,030)	\$ 8,165		



GAAP - Non-GAAP Reconciliation

\$ in 000s

		RESTATED	RESTATED	RESTATED	RESTATED		RESTATED	RESTATED	RESTATED	RESTATED		RESTATED		,
		Quarter Ending	Quarter	Quarter	Quarter		Quarter	Quarter	Quarter	Quarter		Quarter	Quarter	Quarter
			Ending	Ending	Ending		Ending	Ending	Ending	Ending		Ending	Ending	Ending
		03/31/2021	06/30/2021	09/30/2021	12/31/2021		03/31/2022	06/30/2022	09/30/2022	12/31/2022		03/31/2023	6/30/2023	9/30/2023
														,
	FY20	Q1-21	Q2-21	Q3-21	Q4-21	FY21	Q1-22	Q2-22	Q3-22	Q4-22	FY22	Q1-23	Q2-23	Q3-23
Total Revenue	58,683	17,330	20,004	20,782			22,237	24,887	26,450	27,678		28,301	29,307	29,474
Total Cost of Revenue	6,507	7 1,547	1,824	2,090	2,203	7,665	2,111	2,257	2,337	2,466	9,171	2,475	2,596	2,604
Gross Profit	\$ 52,176	\$ 15,783	\$ 18,180	\$ 18,691	\$ 19,691	\$ 72,346	\$ 20,126	\$ 22,630	\$ 24,113	\$ 25,212	\$ 92,081	\$ 25,826	\$ 26,712	\$ 26,870
Sales & Marketing	7,804	2,489	3,133	2,882	2,921	11,424	3,287	3,840	3,539	3,296	13,963	4,160	4,708	4,301
Depreciation/Amortization Expense	2,734	628	901	1,120	1,272	3,922	1,337	1,462	1,780	2,068	6,647	2,215	2,329	2,349
Other Operating Expenses	36,142	11,515	11,580	12,819	14,960	50,874	15,540	18,659	18,061	18,383	70,644	20,104	20,049	21,118
Total Other Income (Expense)	(82)	(22)) (16)	(16)) (16)	(70)	(16)	(19)	(25)	(72)	(133)	3,821	(107)	(6)
Total Income Taxes	(7,755)	(694)) (628)	(576)	389	(1,509)	(38)	(475)	(41)	622	68	842	(161)	(188)
Net Income (Loss)	\$ 13,167	\$ 1,823	\$ 3,178	\$ 2,431	\$ 134	\$ 7,565	\$ (17)	\$ (875)	\$ 748	\$ 771	\$ 627	\$ 2,326	\$ (320)	\$ (716)
Net Interest Expense	79	22	16	16	16	70	16	19	25	72	133	50	15	6
Income Taxes	(7,755)	(694)) (628)	(576)) 389	(1,509)	(38)	(475)	(41)	622	68	842	(161)	(188)
Depreciation and Amortization Expense	2,734	628	901	1,120	1,272	3,922	1,337	1,462	1,780	2,068	6,647	2,215	2,329	2,349
EBITDA	\$ 8,227	\$ 1,779	\$ 3,467	\$ 2,991	\$ 1,811	\$ 10,048	\$ 1,298	\$ 131	\$ 2,512	\$ 3,533	\$ 7,475	\$ 5,433	\$ 1,863	\$ 1,451
Stock Based Compensation	886	246	284	297	229	1,056	324	340	306	304	1,274	266	417	526
Loss on Disposition/Impairment	(51)) 65	(44)	(4)) 10	27	7	89	264	50	410	65	144	905
Acquisition Expenses	42	1,359	39	3	20	1,422	155	2,074	47	81	2,356	142	716	15
Other (Income)/Expense, net						-					-	(3,871)) 92	<u>-</u>
Adjusted EBITDA	\$ 9,103	\$ 3,449	\$ 3,746	\$ 3,287	\$ 2,070	\$ 12,552	\$ 1,783	\$ 2,635	\$ 3,129	\$ 3,968	\$ 11,515	\$ 2,035	\$ 3,232	\$ 2,897



Contact Information



Peter D. Holt, President & CEO peter.holt@thejoint.com

The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Jake Singleton, CFO jake.singleton@thejoint.com

The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Kirsten Chapman, LHA Investor Relations thejoint@lhai.com

LHA Investor Relations | 50 California Street, Suite 1500 | San Francisco, CA 94111 | (415) 433-3777



https://www.facebook.com/thejointchiro@thejointchiro



https://twitter.com/thejointchiro@thejointchiro



https://www.youtube.com/thejointcorp@thejointcorp

